Diabetes PubMed

Pioglitazone is the preferred thiazolidinedione to reduce cardiovascular risk in people with type 2 diabetes.

This suggests that a 24-week treatment with pioglitazone or bed-time insulin has a similar impact on intra-abdominal fat mass and systemic low-grade inflammation.

These findings strongly suggest that pioglitazone has an important place in the management of type 2 diabetes.

To the best of our knowledge this is the first reported case of pancytopenia induced by pioglitazone therapy.

These results indicate that pioglitazone may enhance the efficiency of glucose metabolism in the brain.

Thus, the combination of pioglitazone with candesartan is potentially a promising therapeutic strategy for type 2 diabetes.

Pioglitazone may offer a novel strategy for the treatment of AD.

The advantages and disadvantages of adding pioglitazone instead of adding basal insulin should be assessed further.

Pioglitazone appears to play an anti-inflammatory role in atherosclerosis process.

We conclude that, in type 2 diabetes mellitus patients, pioglitazone-but not rosiglitazone-significantly raised sRAGE, which may contribute to its antiatherogenic effects.

Pioglitazone also had a favourable risk profile compared with rosiglitazone; although this requires replication in other studies, it may have implications for prescribing within this class of drugs.

Pioglitazone improves glucose metabolism and insulin-resistance compared to acarbose in type 2 diabetic patients already treated with metformin and sulphonilureas.

The efficacy and safety of adding pioglitazone to either metformin monotherapy or sulphonylurea monotherapy were good.

Using a low dose regimen, pioglitazone significantly improved blood pressure and hepatic function and may be more effective than metformin to reduce risk factors in Japanese diabetic patients with metabolic syndrome at preventing atherosclerosis.

These results suggest that abdominal fat redistribution preferentially reflects the anti-inflammatory benefits of pioglitazone treatment.